Second generation hybrid polar compounds are potent inducers of transformed cell differentiation

Richon, VM; Webb, Y; Merger, R; Sheppard, T; Jursic, B; Ngo, L; Civoli, F; Breslow, R; Rifkind, RA; Marks, PA

HERO ID

4932978

Reference Type

Journal Article

Year

1996

Language

English

PMID

8650156

HERO ID 4932978
In Press No
Year 1996
Title Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
Authors Richon, VM; Webb, Y; Merger, R; Sheppard, T; Jursic, B; Ngo, L; Civoli, F; Breslow, R; Rifkind, RA; Marks, PA
Journal Proceedings of the National Academy of Sciences of the United States of America
Volume 93
Issue 12 (June 11
Page Numbers 5705-5708
Abstract Hybrid polar compounds, of which hexamethylenebisacetamide (HMBA) is the prototype, are potent inducers of differentiation of murine erythroleukemia (MEL) cells and a wide variety of other transformed cells. HMBA has been shown to induce differentiation of neoplastic cells in patients, but is not an adequate therapeutic agent because of dose-limiting toxicity. We report on a group of three potent second generation hybrid polar compounds, diethyl bis-(pentamethylene-N,N-dimethylcarboxamide) malonate (EMBA), suberoylanilide hydroxamic acid (SAHA), and m-carboxycinnamic acid bis-hydroxamide (CBHA) with optimal concentrations for inducing MEL cells of 0.4 mM, 2 microM, and 4 microM, respectively, compared to 5 mM for HMBA. All three agents induce accumulation of underphosphorylated pRB; increased levels of p2l protein, a prolongation of the initial G1 phase of the cell cycle; and accumulation of hemoglobin. However, based upon their effective concentrations, the cross-resistance or sensitivity of an HMBA-resistant MEL cell variant, and differences in c-myb expression during induction, these differentiation-inducing hybrid polar compounds can be grouped into two subsets, HMBA/EMBA and SAHA/CBHA. This classification may prove of value in selecting and planning prospective preclinical and clinical studies toward the treatment of cancer by differentiation therapy.
Doi 10.1073/pnas.93.12.5705
Pmid 8650156
Wosid WOS:A1996UQ45500007
Is Certified Translation No
Dupe Override No
Is Public Yes
Language Text English
Keyword Index Medicus; 1996)